March 23rd 2025, PDC*line Pharma is presenting new results from its ongoing clinical development program at the European Lung Cancer Congress 2025, during the poster session — in the presence of our...
PDC*line Pharma presents primary clinical results from phase I/II trial on PDC*lung01 cancer vaccine at ESMO-IO 2024
PDC*lung01, in combination with pembrolizumab, demonstrates the potential to provide...
Intermediary results of high dose PDC*lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patients
Combinatio...
PDC*line Pharma and partners receive €8.1M from Walloon region and Wallonia health cluster BioWin for personalized therapeutic vaccine project
- PDC*neo+ project aims to develop personalized therapeutic...
PDC*line Pharma completes enrolment of four cohorts of patients
in PDC-LUNG-101 phase I/II clinical trial.
Total of 67 patients dosed in four cohorts in PDC-LUNG-101 trial with PDC*lung01...
Treatment with PDC*lung01 induces anti-tumor immune response in significant number of patients which appears to be enhanced by combination with pembrolizumab
Liège, Belgium, and Grenoble, France...
Preliminary results with PDC*lung01 in monotherapy and at low dose with pembrolizumab evoke acceptable safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer...
PDC*line Pharma raises €17.5 million ($20,3M) in Series B2 financing round
New funding includes €11.8M in equity and €5.7M in grants. It completes the €20M B1 round of financing announced in January...
B2 cohort (high dose added to anti-PD-1) of the PDC-LUNG-101 trial with PDC*lung01 therapeutic cancer vaccine candidate for non-small cell lung cancer has been opened and first patients were dosed
...
PDC*line Pharma, a biotech company developing a novel class of potent and off-the-shelf cancer immunotherapies to treat cancer patients, today announced that the Company will give presentations and...
